肿瘤细胞治疗研究
ALL SOURCES
Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR-T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lu
这些发现建立了一个具有临床转化价值的联合治疗框架，用以增强 CAR-T 疗法在实体瘤中的疗效与持久性。
CAR T Cell Therapy in Lung Cancer: Overcoming Tumor Microenvironment-Mediated Barriers.
嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤中取得了显著的临床成功。
The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer.
小细胞肺癌（SCLC）是一种侵袭性恶性肿瘤，有效治疗选择有限。
HMGCS1 drives cholesterol-dependent membrane repair and shields tumor cells from lymphocyte attack.
细胞毒性淋巴细胞利用穿孔素在肿瘤细胞的质膜（PM）上形成孔道，从而使颗粒酶介导的细胞死亡得以发生。
B7-H3 (CD276) in exosome biogenesis and the tumor microenvironment: a new therapeutic nexus.
肿瘤来源外泌体是癌症进展的强大介质，影响肿瘤微环境（TME）以促进免疫逃逸、转移和治疗耐药。
Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer.
CAR-T（CAR-T）细胞疗法在实体瘤中面临关键障碍，包括浸润不良、T 细胞耗竭和免疫抑制微环境，导致缓解率低于 10%。
Tumour immunotherapy in solid and hematologic malignancies: Progress, challenges, and a practical framework.
肿瘤免疫治疗通过将免疫监视、免疫编辑和检查点生物学的基础见解转化为有效的临床策略，重塑了肿瘤学的格局。
Engineered nanovesicles as a DC vaccine to enhance the antitumor efficacy of CAR-T cells against solid tumors.
本研究建立了一种新的联合策略，利用靶向 CD205 的肿瘤细胞来源 NVs 作为 DC 疫苗，有效重编程免疫抑制性 TME。
Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma.
胰腺导管腺癌（PDAC）和肺腺癌（LUAD）仍是致命性恶性肿瘤，治疗选择有限，凸显了开发更有效治疗方法的迫切需求。
How diverse therapeutic strategies reshape the tumor immune microenvironment in small cell lung cancer: from radiation to engineered immunotherapies.
小细胞肺癌（SCLC）是一种侵袭性强、免疫学上呈“冷”特征的恶性肿瘤，以深度免疫抑制和对免疫治疗反应有限为特征。
MEMBER ACCOUNT
登录成功会直接打开下一页。
